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The Global Mental Health (GMH) movement has played 
a pivotal part in bringing to attention the unmet needs 
of patients with mental disorders, particularly in low-
income and middle-income countries.1,2 Sch izophrenia 
is of primary concern in view of the high level of 
associated disability and stigma, and the risk that, 
without treatment, patients will experience prolonged 
institutionalisation, neglect, and abuse.3–5
Sudipto Chatterjee and colleagues’ multicentre, 
randomised controlled COmmunity care for People 
with Schizophrenia in India (COPSI) trial,6 in The Lancet, 
represents a milestone by showing the beneﬁ ts of 
a collaborative community-based care plus facility-
based care model compared with conventional 
facility-based care alone for treatment of moderate 
to severe schizophrenia. However, implementation of 
collaborative community-based care in low-income and 
middle-income countries has several issues that need 
further consideration, such as ensuring continuity in 
supervision of community workers, safeguarding the 
physical health of patients, and embedding services 
within the local context and culture.
Collaborative community-based care makes sense: 
physical facilities (eg, clinics and hospitals) are not 
needed, demand on professional skills is low, and the 
family remains the core unit of care. COPSI is the ﬁ rst trial 
to test collaborative community-based care rigorously 
in a developing country, India.6 187 participants were 
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of psychotherapy is undoubted, the evidence base for 
its eﬀ ect size is less solid than that for antidepressants.4 
The main reason for this weaker evidence is the diﬃ  culty 
in deﬁ nition of valid control groups and the fact that 
therapists, patients, and often even raters are not masked. 
Outcome in psychotherapy control groups has even 
been found to be signiﬁ cantly worse than that in pill 
placebo groups (the so-called nocebo eﬀ ect), because 
patients are fully aware of their study situation.10 Testing 
psychotherapy against a nocebo condition could therefore 
lead to artiﬁ cially large group diﬀ erences and eﬀ ect sizes.
In summary, the present approach to estimation of 
the beneﬁ ts of antidepressant treatments is likely to 
underestimate the clinical signiﬁ cance of antidepressants 
and overestimate that of psychotherapy. At the same 
time, we are experiencing an increasing tendency to 
medicalise individuals who have emotional reactions to 
diﬃ  cult life circumstances but without any clinical signs 
of depression, and to oﬀ er them antidepressants or 
psychotherapy which might not be appropriate to their 
needs.11 We should be careful not to oﬀ er our treatments 
to the wrong patients, but to provide them consistently 
to the right patients.
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randomised to receive community-based care, and 95 to 
facility-based care alone. At 12 months, the collaborative 
community-based care intervention showed a non-
signiﬁ cant improvement in symptoms of psychosis as 
measured by the positive and negative symptom scale 
(PANSS), and a clearer diﬀ erence in improvement of 
disability according to the Indian disability evaluation 
and assessment scale [IDEAS]; (PANSS adjusted 
mean diﬀ erence –3·75, 95% CI –7·92 to 0·42; p=0·08; 
IDEAS –0·95, –1·68 to –0·23; p=0·01). Furthermore, 
adherence to treatment was higher in the intervention 
group (adjusted odds ratio 2·93, 95% CI 1·34–6·39; 
p=0·01). Collaborative community-based care was 
no more eﬀ ective than facility-based care alone for 
reducing stigma and discrimination, alleviating carer 
burden, or improving illness-relevant knowledge 
amongst family members. In assessment of these 
outcomes, it is important to keep in mind that chronic 
schizophrenia is a disabling disorder that is diﬃ  cult to 
treat in any situation. Noteworthy, therefore, is that 
ﬁ ndings from COPSI were broadly the same as those 
from similar trials of collaborative community-based 
care done in high-income countries.6
What lessons can be learned from COPSI? Supervision 
was the most costly component of the collaborative 
community-based care intervention. Maintenance 
of supervision in very low resource settings is a major 
challenge, because of cost and the perennial issue of loss 
of skilled professionals. In Timor-Leste, for example, 
discontinuation of donor funding in 2005 left 15 national 
community mental health workers with no professional 
supervision for 3 years, until the return of the ﬁ rst trained 
Timorese psychiatrist.7 Scarcity of supervision results in 
worker isolation, demoralisation, and attenuation of skills. 
Assessments can become cursory, leading to misdiagnosis 
and inaccurate prescribing of psychotropic drugs, which 
are commonly dispensed for indeﬁ nite periods without 
critical review. These practices increase the prevalence 
of serious adverse eﬀ ects, particularly the metabolic 
syndrome with modern atypical antipsychotic drugs.8
India oﬀ ers an important case in point. The population 
is at increased genetic risk for type 2 diabetes, with 
rising obesity in adolescents and young adults adding 
to the epidemic.9 Prescription of antipsychotic drugs 
for schizophrenia—a disorder for which onset peaks in 
adolescence and young adulthood—greatly increases risk 
of the metabolic syndrome.10 People with schizophrenia 
are at risk of cardiovascular disease because of their 
high rates of smoking and poor attention to diet 
and exercise.11 Therefore, the GMH movement needs 
to confront the reality that rollout of collaborative 
community-based care for schizophrenia, particularly 
in poorly supervised settings, might add to the looming 
epidemic of cardiovascular disease. There can be no 
mental health without physical health, and the challenge 
is to devise strategies to support community mental 
health workers in monitoring and responding to the 
health risks associated with treatment of schizophrenia 
in low-resource environments—a formidable task.
A key criticism of the GMH movement is that it has 
blinded itself to the complexity of culture in its haste to 
roll out packaged programmes of care in low-income and 
middle-income countries.12 In many cultures, psychotic 
symptoms are still attributed to curses, spirit possession, 
and communication with ancestors, and patients 
commonly ﬁ rst consult a traditional or religious leader for 
assistance.13 Introduction of evidence-based treatments 
without acknowledgment of the cultural meaning of 
illnesses and traditional approaches to healing can result 
in confusion amongst patients and carers. At worst, 
competition and even tension might develop between 
clinical services and traditional healers. Unfortunately, 
however, the stridency with which the cultural message 
has been presented risks blunting its eﬀ ect on mainstream 
psychiatry.12 A strong consensus already exists that 
the ﬁ rst step in initiation of mental health services in 
low-income and middle-income countries includes a 
comprehensive analysis of the culture, context, history, 
prevailing health belief systems, social structures, and 
politics of funding in each setting.
Sustaining of mental health initiatives, particularly 
in low-resource settings, needs a comprehensive, 
multisectoral approach based on genuine engagement 
with the community. The sense of local ownership and 
involvement is essential to ensure that the complexities 
of disorders such as schizophrenia are addressed at both 
a clinical and wider social level. Social programmes are 
needed to overcome stigma and discrimination, relieve 
carer burden, and educate families about the nature 
of the disorder—areas in which COPSI was notably less 
successful. These social components of interventions 
are often best provided by local non-government 
agencies and voluntary associations, whereas core 
services attend to the direct clinical needs of patients.
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Schizophrenia causes substantial disability and premature 
mortality, and is one of the top causes of disease 
burden worldwide.1 Antipsychotic drugs revolutionised 
schizophrenia treatment when introduced in the 1950s, 
and numerous studies have shown that antipsychotics 
are eﬀ ective for acute episodes, and as maintenance 
treatment, with a number needed to treat of 3 to prevent 
relapse.2 Evidence has also shown that some drugs could 
reduce mortality, mainly through a reduction in suicide 
rates.3 However, the clinical reality is that many patients 
stop taking antipsychotics for various reasons: side-
eﬀ ects, absence of beneﬁ t, disorganisation, and because 
they do not perceive they have an illness.
Although more than 20 diﬀ erent antipsychotics 
are in use for ﬁ rst-line treatment of schizophrenia, all 
essentially use the same mechanism, and drugs that use 
alternative mechanisms have yet to reach the market.4,5 
Consequently, patients are faced with Hobson’s choice: 
antipsychotic treatment or nothing. This choice is further 
complicated because antipsychotics are associated with 
several distressing and potentially serious side-eﬀ ects, 
including tardive dyskinesia, endocrine and sexual 
dysfunction, and cardiac dysrhythmia.6–9 Therefore, a 
viable treatment alternative is needed.
In The Lancet, Anthony Morrison and colleagues’ 
randomised trial10 provides ground-breaking evidence 
that cognitive therapy might be such an alternative. 
Cognitive therapy is a structured time-limited treatment 
that involves the therapist working collaboratively with 
the patient in weekly sessions over several months to 
reappraise psychotic experiences and modify unhelpful 
thought patterns and behaviours. Cognitive therapy is 
established as eﬀ ective in treatment of schizophrenia, 
but in the past has always been used as an adjunct 
to antipsychotic treatment for patients with residual 
symptoms.11 Morrison and colleagues assessed the beneﬁ t 
of cognitive therapy for treatment of schizophrenia in 
patients who chose not to take antipsychotic drugs. 
The investigators randomly assigned 37 patients to 
cognitive therapy plus treatment as usual and 37 patients 
to treatment as usual alone, with a primary endpoint 
of total score on the Positive and Negative Syndrome 
Scale (PANSS). Patients received follow-up over at 
least 9 months. Cognitive therapy proved to be highly 
eﬀ ective in reducing psychotic symptoms, and in 
improving function compared with treatment as usual; 
mean PANNS total scores were consistently lower in the 
cognitive therapy group than in the treatment as usual 
Cognitive therapy: at last an alternative to antipsychotics?
The active involvement of local leadership and stake-
holder groups is crucial to sustain and develop programmes; 
mental health for all means all need to play a part. 
Therefore, as services are rolled out across low-income 
and middle-income countries, the global must engage 
with the local to forge an equal partnership to improve the 
lives of people with schizophrenia and their families.
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